NPCE vs. LUNG, BVS, ANIK, SKIN, PLSE, TCMD, CERS, NVRO, OSUR, and SRDX
Should you be buying NeuroPace stock or one of its competitors? The main competitors of NeuroPace include Pulmonx (LUNG), Bioventus (BVS), Anika Therapeutics (ANIK), Beauty Health (SKIN), Pulse Biosciences (PLSE), Tactile Systems Technology (TCMD), Cerus (CERS), Nevro (NVRO), OraSure Technologies (OSUR), and Surmodics (SRDX). These companies are all part of the "surgical & medical instruments" industry.
Pulmonx (NASDAQ:LUNG) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations.
Pulmonx currently has a consensus target price of $16.33, suggesting a potential upside of 81.48%. NeuroPace has a consensus target price of $15.67, suggesting a potential upside of 83.67%. Given Pulmonx's stronger consensus rating and higher possible upside, analysts plainly believe NeuroPace is more favorable than Pulmonx.
NeuroPace has lower revenue, but higher earnings than Pulmonx. NeuroPace is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.
In the previous week, NeuroPace had 20 more articles in the media than Pulmonx. MarketBeat recorded 23 mentions for NeuroPace and 3 mentions for Pulmonx. NeuroPace's average media sentiment score of 1.10 beat Pulmonx's score of 0.41 indicating that Pulmonx is being referred to more favorably in the media.
91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 5.7% of Pulmonx shares are owned by company insiders. Comparatively, 22.2% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Pulmonx received 6 more outperform votes than NeuroPace when rated by MarketBeat users. However, 55.81% of users gave NeuroPace an outperform vote while only 43.48% of users gave Pulmonx an outperform vote.
Pulmonx has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, NeuroPace has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500.
NeuroPace has a net margin of -45.61% compared to NeuroPace's net margin of -80.46%. NeuroPace's return on equity of -48.09% beat Pulmonx's return on equity.
Summary
NeuroPace beats Pulmonx on 11 of the 18 factors compared between the two stocks.
Get NeuroPace News Delivered to You Automatically
Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NPCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroPace Competitors List
Related Companies and Tools
